$FBP

$100 Invested In First BanCorp 10 Years Ago Would Be Worth This Much Today - First BanCorp (NYSE:FBP)

First BanCorp ( NYSE:FBP ) has outperformed the market over the past 10 years by 6.19% on an annualized basis producing an average annual return of 18.44%. Currently, First BanCorp has a market capitalization of $3.11 billion.

Original reporting
Benzinga · Benzinga Insights
Published Nov 25, 2025, 3:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 25, 2025, 4:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
$100 Invested In First BanCorp 10 Years Ago Would Be Worth This Much Today - First BanCorp (NYSE:FBP) — source image
Decision brief

The 30-second read

$FBPNeutralMed
01

Why it matters

The company's historical performance suggests resilience, but current economic conditions and sector trends should be monitored.

02

Market read

The news underscores the company's strong long-term track record, which may influence investor confidence.

03

What to watch

Potential regulatory changes or interest rate fluctuations could impact profitability.

Timing: Long-term perspective; short-term trading impact limited.

Background

First BanCorp has shown consistent growth over the past decade, outperforming the market and maintaining a solid market cap of $3.11 billion.

Company-level read

Ticker impact

$FBPNeutralMedium confidence
Context

High relevance due to 10-year performance data and current market capitalization.

Expected impact

Stable to modest appreciation in the near term, with potential for continued growth if current trends persist.

Evidence & confidence

Historical outperformance suggests robustness, but market dynamics and economic factors could influence future performance.

Market effects

Positive signal for regional banking sector, indicating stability and growth potential.

Limited impact; specific to regional banking stocks.

Minimal; focused on regional bank performance.

Counterpoint

Past performance may not predict future results; economic downturns or sector-specific issues could adversely affect FBP.

Key entities

  • First BanCorp

    A regional bank with a focus on commercial banking services.

Related articles

$FBPMedAI 8/10

First BanCorp (FBP) Q2 2026 Earnings Call Transcript

First BanCorp (FBP) Q2 2026 earnings call reported net income of $96.1 million, or $0.63 per diluted share, up from $88 million, or $0.57 last quarter. CET1 was 17%. Loan growth accelerated to $13.3 billion total loans, up 5% annualized linked-quarter basis, with $1.7 billion originations. Net interest income rose to $229.1 million; NIM 4.87%.

$FBPMed

FIRST BANCORP /PR/ (FBP): Completion of Acquisition or Disposition of Assets

FIRST BANCORP /PR/ (FBP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.1 2 exhibit991.htm EXHIBIT 99.1 exhibit991 Exhibit 99.1 FIRST BANCORP. ANNOUNCES EARNINGS FOR THE QUARTER ENDED JUNE 30, 2026 SAN JUAN, Puerto Rico – July 22, 2026 – First BanCorp. (the “Corporation” or “First BanCorp.”) (NYSE: FBP), the bank holding company for FirstBank P

$FBPMedAI 8/10

First BanCorp. (NYSE:FBP) Reaches New 52

First BanCorp. (NYSE:FBP) hit a new 52-week high mid-day Wednesday, trading as high as $24.64 and last at $24.4190 versus a prior close of $24.46, with volume of 25,394 shares. Analysts cited include Wells Fargo raising its target to $26.00. The bank reported Q1 EPS of $0.57 (vs. $0.52) and declared a $0.20 quarterly dividend payable June 12.

$BKRMed

Baker Hughes (BKR) Secures Order For 76 Gas Turbines

Baker Hughes (BKR) secured an order for 76 NovaLT™16 gas turbines from Dynamis Power Solutions, valued at 1.3 GW, for hypermobile power projects. The turbines are designed for rapid deployment in data centers and oil and gas operations, aligning with Baker Hughes' focus on distributed power and digital infrastructure. Analysts view this as part of the company's strategy for higher-margin, recurring revenue streams.

$AMGNLowAI 8/10

Evolocumab before PCI for acute MI improves LDL control

Amgen's evolocumab (Repatha) improved LDL control in acute MI patients by 1 year when administered early, but did not impact clinical outcomes vs. standard care, according to the AMUNDSEN trial presented at the European Society of Cardiology Congress and published in JAMA. 82% of patients on evolocumab met LDL targets vs. 40% on standard care alone.